Is BeOne Medicines Ltd. (ONC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.2% / 30% | 7.9% / 30% | 2.1% / 30% | 1.26% / 5% | ✓ HALAL |
| DJIM | 3.2% / 33% | 7.9% / 33% | 2.1% / 33% | 1.26% / 5% | ✓ HALAL |
| MSCI | 18.2% / 33% | 44.4% / 33% | 12.0% / 33% | 1.26% / 5% | ✗ NOT HALAL |
| S&P | 3.2% / 33% | 7.9% / 33% | 2.1% / 33% | 1.26% / 5% | ✓ HALAL |
| FTSE | 18.2% / 33% | 44.4% / 33% | 12.0% / 50% | 1.26% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 87.5% | |
| Operating Margin | 12.4% | |
| Net Margin | 5.4% | |
| Return on Equity (ROE) | 7.5% | |
| Return on Assets (ROA) | 4.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $1.1B |
| Free Cash Flow | $861M |
| Total Debt | $1.1B |
| Debt-to-Equity | 25.1 |
| Current Ratio | 3.4 |
| Total Assets | $8.2B |
Price & Trading
| Last Close | $276.95 |
| 50-Day MA | $323.77 |
| 200-Day MA | $314.51 |
| Avg Volume | 272K |
| Beta | 0.5 |
|
52-Week Range
$196.45
| |
About BeOne Medicines Ltd. (ONC)
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Purification Calculator
As a halal stock with 1.26% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BeOne Medicines Ltd. (ONC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BeOne Medicines Ltd. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BeOne Medicines Ltd.'s debt ratio?
BeOne Medicines Ltd.'s debt ratio is 3.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 18.2%.
Does BeOne Medicines Ltd. require dividend purification?
Yes, BeOne Medicines Ltd. has an impermissible income ratio of 1.26%, which means 1.26% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are BeOne Medicines Ltd.'s key financial metrics?
BeOne Medicines Ltd. has a market capitalization of $32.5B, trailing P/E ratio of 115.1, and revenue of $5.3B. The company maintains a gross margin of 87.5% and a net margin of 5.4%. Return on equity stands at 7.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.